iCAD’s Breast AI Suite offers a comprehensive portfolio of clinically proven technologies for breast cancer detection, automated breast density assessment, and short-term personalized risk evaluation.1-4

Designed to deliver superior clinical performance, our powerful suite of breast AI solutions is expertly engineered to optimize operational efficiency, clinician confidence and patient outcomes.1-4

Together, these solutions offer a more holistic view of a woman’s present and future, empowering clinicians to personalize breast cancer screening like never before.

The only complete AI solution designed to assist clinicians and facilities in addressing the top breast imaging challenges

**Benefits**

Unrivaled by any other breast imaging AI solution available today5

Expertly engineered to enhance breast cancer screening, augment radiologist performance and improve patient lives1-4

Designed to help radiologists standardize results, manage workload volume and reduce burnout1-4

Offers a more holistic approach to personalized screening

Provides a more complete picture to increase health equity
Cancer Detection

ProFound AI® is raising the bar on detection performance. Trained with one of the largest available DBT datasets, this high-performing, concurrent read cancer detection and workflow solution rapidly and accurately analyzes each DBT image, detecting both malignant soft tissue densities and calcifications with unrivaled accuracy.1,4,5 This innovative solution provides radiologists with key information, such as Certainty of Finding lesion and Case Scores, which assists in prioritizing caseloads, clinical decision-making and may help to reduce physician burnout.

With about two times the improvement in clinical performance compared to leading competitors,3 ProFound AI offers a trifecta of clinically proven benefits for physicians and patients, including an 8 percent improvement in sensitivity, a 7 percent improvement in specificity, and a 52.7 percent reduction in reading time for radiologists.1 The latest version of the technology offers up to a 10% improvement in specificity performance while maintaining and industry-leading high sensitivity level, along with up to 40% faster processing compared to previous versions of our technology.4

ProFound AI flexibly integrates with major PACS, offering an intuitive, system-wide solution for improved workflow and decision support in any reading environment.

Density Assessment

The world’s first multi-vendor deep learning algorithm for accurate automated breast density assessments, PowerLook® Density Assessment software simplifies and standardizes breast density stratification and reporting, with accurate and reliable results.4,6 Using mammographic images, it analyzes the woman’s breast anatomy and categorizes her breast density within the appropriate BI-RADS® 5th edition density category. This innovative solution automates the process of breast density reporting and empowers clinicians to further personalize breast cancer screening recommendations for patients.

Risk Evaluation

With ProFound AI® Risk, patient care has never been more personalized. The world’s first clinical decision support tool that provides an accurate short-term, breast cancer risk estimation that is truly personalized for each woman. ProFound AI Risk provides superior insights2,3 that empower clinicians to tailor a woman’s breast screening regimen and potentially identify cancers earlier. This easy-to-implement solution uniquely combines a range of risk factors, offering superior performance in assessing short-term risk compared to traditional breast cancer risk models.2-4

Specifically designed to factor in racial and ethnic backgrounds, ProFound AI Risk offers an equitable and inclusive approach to precision screening.4 The algorithm also factors in clinically relevant global screening guidelines and more than 15 country incidence and mortality reference tables, for alignment with that country’s general population.

---

4. iCAD data on file. Standalone performance varies by vendor.
5. Based on FDA 510K submissions K182373, K201019, K193229.
6. Based on publicly available data as of September 2021. For GE and Hologic only. Uses 2D synthesized images.